Hints and tips:
...JPMorgan Chase is poised to collect the largest individual fee to a bank for selling a company, earning $123m for advising Botox-maker Allergan on a planned $63bn sale to US pharmaceutical group AbbVie....
...Appaloosa currently holds a 0.35 per cent stake in Allergan, according to Eikon data, making it Allergan’s 44th largest shareholder....
...The firm’s original investment in Allergan was a money-spinner, reaping gains of $2.3bn before the company agreed a sale to Actavis....
...The relevant SEC filings were made by Allergan, Inc. prior to its acquisition by Actavis plc....
...by Actavis, the generic drugs arm of US-based Allergan....
...Less than a year later Forest was acquired by Actavis (which subsequently merged with Allergan) resulting in massive gains for Forest shareholders....
...In 2013 Ireland-based Warner Chilcott bought US-based Actavis, then in 2015, Actavis bought US-based Allergan....
...Allergan, previously known as Actavis, was itself one of numerous lesser-known US companies to have “redomiciled” to Ireland or other lower-tax countries....
...How did we get into this world of corporate flux, in which companies such as Valeant and Actavis, which acquired Allergan and renamed itself, gobble up others before most people have learnt their peculiar...
...Allergan (formerly known as Actavis and before that as Watson) describes itself as pioneering a new model in the drug sector....
...It is just over a year since Brent Saunders became chief executive of Allergan, then known as Actavis, but he has changed the company beyond recognition....
...Shortly after, Pfizer contacted Actavis, as Allergan was then known, about a potential deal, but the overture did not result in discussions....
...The remarks came in a ruling on Thursday that overturned Pfizer’s UK patent for use of Lyrica against pain and rejected its claim of patent infringement by Actavis, the generic drugs arm of US-based Allergan...
...The purchase underscores the increasing importance of the cosmetic dermatology market for Allergan, which recently changed its name from Actavis after last year paying $70bn for the maker of Botox and facial...
...Last November, drugmaker Actavis clinched a $66bn deal for Allergan, best known for its Botox treatment but whose biggest business was eyecare products (Actavis later rebranded itself as Allergan)....
...Others include Actavis, which bought Allergan, the maker of Botox, last year for $66bn and has since adopted the Allergan name....
...Valeant tried to buy Allergan in a bitter takeover war last year, but lost out to Actavis, which acquired the group for $70bn before adopting its name....
...Actavis is preparing to change its name to Allergan, the third name change in as many years....
...Actavis funded its Allergan deal with a $21bn bond offering, the second-biggest corporate debt offering on record after Verizon’s $50bn issue....
...David Pyott, CEO of Allergan, could receive $118m if he leaves following his company’s acquisition by pharmaceuticals rival Actavis....
...been taken over by the Dublin-based Actavis....
...After Actavis completes its $66bn takeover of Allergan in a few months, his job will be taken by Brent Saunders, who appeared as a white knight buyer in October, during an ugly 10-month takeover battle in...
...Actavis sold $21bn of bonds on Tuesday in the second-largest corporate debt offering on record, to help fund its $66bn acquisition of Botox-maker Allergan....
...Actavis has responded by shifting towards higher-value branded products, culminating in its $72.7bn acquisition of Allergan, maker of Botox, last November....
...purchase of Allergan....
International Edition